Blocking Aggressive Prostate Cancer’s Fat-burning Mechanism Overcomes Disease’s Resistance to Xtandi

Blocking Aggressive Prostate Cancer’s Fat-burning Mechanism Overcomes Disease’s Resistance to Xtandi
A major problem treating an aggressive form of prostate cancer is that it develops resistance to the androgen therapies used to combat it. One solution could be targeting the cancer's energy-creating mechanism, according to a study. Prostate cancer burns fat to create energy. Researchers discovered that blocking this metabolism process makes an androgen treatment known as Xtandi (enzalutamide) more effective against castration-resistant prostate cancer, or CRPC. The preclinical-trial study, conducted in prostate cancer cells grown in a lab and in animal models, showed that a CPT1A inhibitor called ranolazine works in synergy with Xtandi to reduce tumor growth. The research, "Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade," was published in the journal Oncotarget. "This is a huge development for men with CRPC who previously did not have many options," Dr. Isabel Schlaepfer, the study's senior author, said in a press release. "There is a critical need for improved therapies for this specific cancer type," said Schlaepfer, an assistant professor at the University of Colorado Cancer Center. Although androgen therapies like Xtandi and Zytiga (abiraterone acetate) help metastatic CRPC patients live longer, virtually all become resistant to the drugs. Most cancers use glucose as their main energy source, but prostate cancer's fuel is lipids, or
Subscribe or to access all post and page content.